Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug
  • Regulatory

Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug

BioSpace

The FDA rejected bitopertin in February amid reports of skepticism from former CBER director Vinay Prasad, who has since departed the agency.

Rare Disease

Read full story

pharminent June 10, 2026 (Last updated: June 10, 2026)

BioSpace

The FDA rejected bitopertin in February amid reports of skepticism from former CBER director Vinay Prasad, who has since departed the agency.

Rare Disease

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Bayer’s asundexian starts EU review for ischaemic stroke
Next: Lilly wins new FDA approval for eczema drug Ebglyss

Related Stories

  • Regulatory

Lilly wins new FDA approval for eczema drug Ebglyss

pharminent June 10, 2026
  • Regulatory

Bayer’s asundexian starts EU review for ischaemic stroke

pharminent June 10, 2026
  • Regulatory

ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval

pharminent June 9, 2026

You May Have Missed

  • Market Access

Aquipta recommended by NICE for acute migraine treatment

pharminent June 10, 2026
  • M&A / Deals

AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

pharminent June 10, 2026
  • Regulatory

Lilly wins new FDA approval for eczema drug Ebglyss

pharminent June 10, 2026
  • Regulatory

Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug

pharminent June 10, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.